Erectile Dysfunction

However, maraviroc's label could eventually be extended to newly-diagnosed patients.

Another new drug in late stage development, Merck & Co.'s integrase inhibitor raltegravir, is expected to be filed with the FDA within the next two months.

With an anticipated launch towards the end of the year, it is also most likely to be used in treatment experienced patients.

Since both drugs offer a novel mechanism of action, Datamonitor expects considerable competition between the two.

Nonetheless, their availability will extend treatment options for patients with more advanced HIV and those with AIDS, making them significant contributors to the growth in the HIV market.

'End Intelliext RELATED NEWS Monogram to get $25 million investment from Pfizer9 May 2006 Pfizer: timely response to industry challenges24 Jan 2007 Pfizer: torcetrapib failure compounds current problems5 Dec 2006 Pfizer: a strategic reversal of fortunes?

27 Jul 2006 Pfizer: no immediate threat to Celebrex from generics 22 Mar 2007 COMPANIES MENTIONED Merck & Co., Inc.

Pfizer Inc YOUR OPINION...

Comment on this Article NEWSLETTERS Sign up to our weekly newsletters for the latest industry news & comment.

I would like to receive Business Digest I would like to receive Drug Delivery News I would like to rec...

Read more...